Haleon plc (HLN) NYSE

8.70

-0.14(-1.58%)

Updated at June 02 04:00PM

Currency In USD

Haleon plc

Address

Building 5

Weybridge, KT13 0NY

United Kingdom of Great Britain and Northern Ireland (the)

Phone

44 1932 822000

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

24561

First IPO Date

July 25, 2022

Key Executives

NameTitlePayYear Born
Brian James McNamaraChief Executive Officer & Executive Director3.85M1966
Dawn Amanda AllenChief Financial Officer & Director2.08M1968
Adrian Charles MorrisGeneral Counsel01967
Bjorn TimelinHead of Strategy0N/A
Filippo LanziPresident of EMEA & LatAm0N/A
Keith ChoyPresident of Asia Pacific01969
Claire DicksonChief Digital & Technology Officer0N/A
Joanne RussellHead of Investor Relations0N/A
Line De DeckerChief Human Resources Officer01974
Namrata PatelChief Supply Chain Officer01966
Tamara RogersChief Marketing Officer01968

Description

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.